Recent Advances in Gene Therapy for Cardiac Tissue Regeneration
Abstract
:1. Introduction
2. Cardiac Tissue Regeneration in Adult Heart
2.1. Mechanisms of Cardiac Tissue Regeneration
2.2. Overview of Strategies to Enhance Cardiac Tissue Regeneration
3. Gene Therapy for Cardiac Tissue Regeneration
3.1. Gene Therapy with Growth Factors for Improving Angiogenesis
3.2. Gene Therapy for Scar Tissue Remodeling
3.3. Gene Therapy to Regulate Reactive Oxygen Species
3.4. Gene Therapy to Reduce Apoptosis
4. Recent Ongoing Clinical Trials
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [Google Scholar] [CrossRef] [PubMed]
- Wilkins, E.; Wilson, L.; Wickramasinghe, K.; Bhatnagar, P.; Leal, J.; Luengo-Fernandez, R.; Burns, R.; Rayner, M.; Townsend, N. European Cardiovascular Disease Statistics 2017; University of Bath: Bath, UK, 2017. [Google Scholar]
- Giedrimiene, D.; King, R. Burden of cardiovascular disease (CVD) on economic cost. Comparison of outcomes in US and Europe. Circ. Cardiovasc. Qual. Outcomes 2017, 10, A207. [Google Scholar] [CrossRef]
- Lähteenvuo, J.; Ylä-Herttuala, S. Advances and Challenges in Cardiovascular Gene Therapy. Hum. Gene Ther. 2017, 28, 1024–1032. [Google Scholar] [CrossRef] [PubMed]
- Braunwald, E. Cell-based therapy in cardiac regeneration: An overview. Circ. Res. 2018, 123, 132–137. [Google Scholar] [CrossRef]
- Liew, L.C.; Ho, B.X.; Soh, B.S. Mending a broken heart: Current strategies and limitations of cell-based therapy. Stem. Cell. Res. Ther. 2020, 11, 138. [Google Scholar] [CrossRef]
- Smagul, S.; Kim, Y.; Smagulova, A.; Raziyeva, K.; Nurkesh, A.; Saparov, A. Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration. Int. J. Mol. Sci. 2020, 21, 5952. [Google Scholar] [CrossRef]
- Raziyeva, K.; Smagulova, A.; Kim, Y.; Smagul, S.; Nurkesh, A.; Saparov, A. Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment. Int. J. Mol. Sci. 2020, 21, 7301. [Google Scholar] [CrossRef]
- Ylä-Herttuala, S.; Baker, A.H. Cardiovascular Gene Therapy: Past, Present, and Future. Mol. Ther. 2017, 25, 1095–1106. [Google Scholar] [CrossRef] [Green Version]
- Ishikawa, K.; Weber, T.; Hajjar, R.J. Human Cardiac Gene Therapy. Circ. Res. 2018, 123, 601–613. [Google Scholar] [CrossRef]
- Shimamura, M.; Nakagami, H.; Sanada, F.; Morishita, R. Progress of Gene Therapy in Cardiovascular Disease. Hypertension 2020, 76, 1038–1044. [Google Scholar] [CrossRef]
- Kieserman, J.M.; Myers, V.D.; Dubey, P.; Cheung, J.Y.; Feldman, A.M. Current Landscape of Heart Failure Gene Therapy. J. Am. Heart Assoc. 2019, 8, e012239. [Google Scholar] [CrossRef]
- Bezzerides, V.J.; Prondzynski, M.; Carrier, L.; Pu, W.T. Gene therapy for inherited arrhythmias. Cardiovasc Res. 2020, 116, 1635–1650. [Google Scholar] [CrossRef]
- Lázár, E.; Sadek, H.A.; Bergmann, O. Cardiomyocyte renewal in the human heart: Insights from the fall-out. Eur. Heart. J. 2017, 38, 2333–2342. [Google Scholar] [CrossRef] [Green Version]
- Bergmann, O.; Bhardwaj, R.D.; Bernard, S.; Zdunek, S.; Barnabé-Heider, F.; Walsh, S.; Zupicich, J.; Alkass, K.; Buchholz, B.A.; Druid, H.; et al. Evidence for cardiomyocyte renewal in humans. Science 2009, 324, 98–102. [Google Scholar] [CrossRef] [Green Version]
- Bergmann, O.; Zdunek, S.; Felker, A.; Salehpour, M.; Alkass, K.; Bernard, S.; Sjostrom, S.L.; Szewczykowska, M.; Jackowska, T.; Dos Remedios, C.; et al. Dynamics of Cell Generation and Turnover in the Human Heart. Cell 2015, 161, 1566–1575. [Google Scholar] [CrossRef] [Green Version]
- Eschenhagen, T.; Bolli, R.; Braun, T.; Field, L.J.; Fleischmann, B.K.; Frisén, J.; Giacca, M.; Hare, J.M.; Houser, S.; Lee, R.T. Cardiomyocyte regeneration: A consensus statement. Circulation 2017, 136, 680–686. [Google Scholar] [CrossRef]
- Verjans, R.; van Bilsen, M.; Schroen, B. Reviewing the Limitations of Adult Mammalian Cardiac Regeneration: Noncoding RNAs as Regulators of Cardiomyogenesis. Biomolecules 2020, 10, 262. [Google Scholar] [CrossRef] [Green Version]
- Lam, N.T.; Sadek, H.A. Neonatal Heart Regeneration: Comprehensive Literature Review. Circulation 2018, 138, 412–423. [Google Scholar] [CrossRef]
- Ahmed, A.; Wang, T.; Delgado-Olguin, P. Ezh2 is not required for cardiac regeneration in neonatal mice. PLoS ONE 2018, 13, e0192238. [Google Scholar] [CrossRef]
- Bassat, E.; Mutlak, Y.E.; Genzelinakh, A.; Shadrin, I.Y.; Baruch Umansky, K.; Yifa, O.; Kain, D.; Rajchman, D.; Leach, J.; Riabov Bassat, D.; et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 2017, 547, 179–184. [Google Scholar] [CrossRef]
- Ingason, A.B.; Goldstone, A.B.; Paulsen, M.J.; Thakore, A.D.; Truong, V.N.; Edwards, B.B.; Eskandari, A.; Bollig, T.; Steele, A.N.; Woo, Y.J. Angiogenesis precedes cardiomyocyte migration in regenerating mammalian hearts. J. Thorac. Cardiovasc. Surg. 2018, 155, 1118–1127.e1111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sampaio-Pinto, V.; Rodrigues, S.C.; Laundos, T.L.; Silva, E.D.; Vasques-Nóvoa, F.; Silva, A.C.; Cerqueira, R.J.; Resende, T.P.; Pianca, N.; Leite-Moreira, A.; et al. Neonatal Apex Resection Triggers Cardiomyocyte Proliferation, Neovascularization and Functional Recovery Despite Local Fibrosis. Stem Cell Rep. 2018, 10, 860–874. [Google Scholar] [CrossRef] [PubMed]
- Zhu, W.; Zhang, E.; Zhao, M.; Chong, Z.; Fan, C.; Tang, Y.; Hunter, J.D.; Borovjagin, A.V.; Walcott, G.P.; Chen, J.Y.; et al. Regenerative Potential of Neonatal Porcine Hearts. Circulation 2018, 138, 2809–2816. [Google Scholar] [CrossRef] [PubMed]
- Ye, L.; D’Agostino, G.; Loo, S.J.; Wang, C.X.; Su, L.P.; Tan, S.H.; Tee, G.Z.; Pua, C.J.; Pena, E.M.; Cheng, R.B.; et al. Early Regenerative Capacity in the Porcine Heart. Circulation 2018, 138, 2798–2808. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Paulsen, M.J.; Hironaka, C.E.; Shin, H.S.; Farry, J.M.; Thakore, A.D.; Jung, J.; Lucian, H.J.; Eskandari, A.; Anilkumar, S.; et al. Natural Heart Regeneration in a Neonatal Rat Myocardial Infarction Model. Cells 2020, 9, 229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Notari, M.; Ventura-Rubio, A.; Bedford-Guaus, S.J.; Jorba, I.; Mulero, L.; Navajas, D.; Martí, M.; Raya, Á. The local microenvironment limits the regenerative potential of the mouse neonatal heart. Sci. Adv. 2018, 4, eaao5553. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Cui, M.; Shah, A.M.; Ye, W.; Tan, W.; Min, Y.L.; Botten, G.A.; Shelton, J.M.; Liu, N.; Bassel-Duby, R.; et al. Mechanistic basis of neonatal heart regeneration revealed by transcriptome and histone modification profiling. Proc. Natl. Acad. Sci. USA 2019, 116, 18455–18465. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Cui, M.; Shah, A.M.; Tan, W.; Liu, N.; Bassel-Duby, R.; Olson, E.N. Cell-Type-Specific Gene Regulatory Networks Underlying Murine Neonatal Heart Regeneration at Single-Cell Resolution. Cell Rep. 2020, 33, 108472. [Google Scholar] [CrossRef]
- Heallen, T.R.; Kadow, Z.A.; Kim, J.H.; Wang, J.; Martin, J.F. Stimulating Cardiogenesis as a Treatment for Heart Failure. Circ. Res. 2019, 124, 1647–1657. [Google Scholar] [CrossRef]
- Zhao, M.T.; Ye, S.; Su, J.; Garg, V. Cardiomyocyte Proliferation and Maturation: Two Sides of the Same Coin for Heart Regeneration. Front. Cell Dev. Biol. 2020, 8, 594226. [Google Scholar] [CrossRef]
- Mohamed, T.M.A.; Ang, Y.S.; Radzinsky, E.; Zhou, P.; Huang, Y.; Elfenbein, A.; Foley, A.; Magnitsky, S.; Srivastava, D. Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration. Cell 2018, 173, 104–116.e112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diez-Cuñado, M.; Wei, K.; Bushway, P.J.; Maurya, M.R.; Perera, R.; Subramaniam, S.; Ruiz-Lozano, P.; Mercola, M. miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway. Cell Rep. 2018, 23, 2168–2174. [Google Scholar] [CrossRef] [PubMed]
- Monroe, T.O.; Hill, M.C.; Morikawa, Y.; Leach, J.P.; Heallen, T.; Cao, S.; Krijger, P.H.L.; de Laat, W.; Wehrens, X.H.T.; Rodney, G.G.; et al. YAP Partially Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo. Dev. Cell. 2019, 48, 765–779.e767. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ali, H.; Braga, L.; Giacca, M. Cardiac regeneration and remodelling of the cardiomyocyte cytoarchitecture. FEBS J. 2020, 287, 417–438. [Google Scholar] [CrossRef]
- Hashimoto, H.; Olson, E.N.; Bassel-Duby, R. Therapeutic approaches for cardiac regeneration and repair. Nat. Rev. Cardiol. 2018, 15, 585–600. [Google Scholar] [CrossRef] [PubMed]
- Huntington, J.; Pachauri, M.; Ali, H.; Giacca, M. RNA interference therapeutics for cardiac regeneration. Curr. Opin. Genet. Dev. 2021, 70, 48–53. [Google Scholar] [CrossRef] [PubMed]
- Shiba, Y. Pluripotent Stem Cells for Cardiac Regeneration-Current Status, Challenges, and Future Perspectives. Circ. J. 2020, 84, 2129–2135. [Google Scholar] [CrossRef]
- Saparov, A.; Chen, C.W.; Beckman, S.A.; Wang, Y.; Huard, J. The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair. Int. J. Mol. Sci. 2013, 14, 16258–16279. [Google Scholar] [CrossRef] [Green Version]
- Madeddu, P. Cell therapy for the treatment of heart disease: Renovation work on the broken heart is still in progress. Free Radic. Biol. Med. 2021, 164, 206–222. [Google Scholar] [CrossRef]
- Tang, J.N.; Cores, J.; Huang, K.; Cui, X.L.; Luo, L.; Zhang, J.Y.; Li, T.S.; Qian, L.; Cheng, K. Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future. Stem Cells Transl. Med. 2018, 7, 354–359. [Google Scholar] [CrossRef]
- Chen, Z.; Chen, L.; Zeng, C.; Wang, W.E. Functionally improved mesenchymal stem cells to better treat myocardial infarction. Stem Cells Int. 2018, 2018, 7045245. [Google Scholar] [CrossRef]
- Baldari, S.; Di Rocco, G.; Piccoli, M.; Pozzobon, M.; Muraca, M.; Toietta, G. Challenges and Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based Therapies. Int. J. Mol. Sci. 2017, 18, 2087. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Zhang, M.; Lu, G.L.; Huang, B.X.; Wang, D.W.; Shao, Y.; Lu, M.J. Hypoxic Preconditioning Enhances Cellular Viability and Pro-angiogenic Paracrine Activity: The Roles of VEGF-A and SDF-1a in Rat Adipose Stem Cells. Front. Cell Dev. Biol. 2020, 8, 580131. [Google Scholar] [CrossRef]
- Ferreira, J.R.; Teixeira, G.Q.; Santos, S.G.; Barbosa, M.A.; Almeida-Porada, G.; Gonçalves, R.M. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning. Front. Immunol. 2018, 9, 2837. [Google Scholar] [CrossRef]
- Mansurov, N.; Chen, W.C.; Awada, H.; Huard, J.; Wang, Y.; Saparov, A. A controlled release system for simultaneous delivery of three human perivascular stem cell-derived factors for tissue repair and regeneration. J. Tissue Eng. Regener. Med. 2018, 12, e1164–e1172. [Google Scholar] [CrossRef]
- Sultankulov, B.; Berillo, D.; Kauanova, S.; Mikhalovsky, S.; Mikhalovska, L.; Saparov, A. Composite Cryogel with Polyelectrolyte Complexes for Growth Factor Delivery. Pharmaceutics 2019, 11, 650. [Google Scholar] [CrossRef] [Green Version]
- Jimi, S.; Jaguparov, A.; Nurkesh, A.; Sultankulov, B.; Saparov, A. Sequential Delivery of Cryogel Released Growth Factors and Cytokines Accelerates Wound Healing and Improves Tissue Regeneration. Front. Bioeng. Biotechnol. 2020, 8, 345. [Google Scholar] [CrossRef]
- Nurkesh, A.; Jaguparov, A.; Jimi, S.; Saparov, A. Recent Advances in the Controlled Release of Growth Factors and Cytokines for Improving Cutaneous Wound Healing. Front. Cell Dev. Biol. 2020, 8, 638. [Google Scholar] [CrossRef]
- Chingale, M.; Zhu, D.; Cheng, K.; Huang, K. Bioengineering Technologies for Cardiac Regenerative Medicine. Front. Bioeng. Biotechnol. 2021, 9, 361. [Google Scholar] [CrossRef]
- Melhem, M.R.; Park, J.; Knapp, L.; Reinkensmeyer, L.; Cvetkovic, C.; Flewellyn, J.; Lee, M.K.; Jensen, T.W.; Bashir, R.; Kong, H.; et al. 3D Printed Stem-Cell-Laden, Microchanneled Hydrogel Patch for the Enhanced Release of Cell-Secreting Factors and Treatment of Myocardial Infarctions. ACS Biomater. Sci. Eng. 2017, 3, 1980–1987. [Google Scholar] [CrossRef]
- Cannatà, A.; Ali, H.; Sinagra, G.; Giacca, M. Gene Therapy for the Heart Lessons Learned and Future Perspectives. Circ. Res. 2020, 126, 1394–1414. [Google Scholar] [CrossRef] [PubMed]
- Ylä-Herttuala, S.; Bridges, C.; Katz, M.G.; Korpisalo, P. Angiogenic gene therapy in cardiovascular diseases: Dream or vision? Eur. Heart J. 2017, 38, 1365–1371. [Google Scholar] [CrossRef] [PubMed]
- Greenberg, B. Gene therapy for heart failure. Trends Cardiovasc. Med. 2017, 27, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Hassinen, I.; Kivelä, A.; Hedman, A.; Saraste, A.; Knuuti, J.; Hartikainen, J.; Ylä-Herttuala, S. Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography. Hum. Gene Ther. 2016, 27, 830–834. [Google Scholar] [CrossRef]
- Braile, M.; Marcella, S.; Cristinziano, L.; Galdiero, M.R.; Modestino, L.; Ferrara, A.L.; Varricchi, G.; Marone, G.; Loffredo, S. VEGF-A in Cardiomyocytes and Heart Diseases. Int. J. Mol. Sci. 2020, 21, 5294. [Google Scholar] [CrossRef]
- Korpela, H.; Järveläinen, N.; Siimes, S.; Lampela, J.; Airaksinen, J.; Valli, K.; Turunen, M.; Pajula, J.; Nurro, J.; Ylä-Herttuala, S. Gene therapy for ischaemic heart disease and heart failure. J. Intern. Med. 2021, in press. [Google Scholar] [CrossRef]
- Apte, R.S.; Chen, D.S.; Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 2019, 176, 1248–1264. [Google Scholar] [CrossRef] [Green Version]
- Mangialardi, G.; Madeddu, P. New vascular endothelial growth factor isoforms promise to increase myocardial perfusion without stealing. Heart 2016, 102, 1697–1698. [Google Scholar] [CrossRef]
- Nurro, J.; Halonen, P.J.; Kuivanen, A.; Tarkia, M.; Saraste, A.; Honkonen, K.; Lähteenvuo, J.; Rissanen, T.T.; Knuuti, J.; Ylä-Herttuala, S. AdVEGF-B186 and AdVEGF-DΔNΔC induce angiogenesis and increase perfusion in porcine myocardium. Heart 2016, 102, 1716–1720. [Google Scholar] [CrossRef]
- Huusko, J.; Lottonen, L.; Merentie, M.; Gurzeler, E.; Anisimov, A.; Miyanohara, A.; Alitalo, K.; Tavi, P.; Ylä-Herttuala, S. AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy. Mol. Ther. 2012, 20, 2212–2221. [Google Scholar] [CrossRef] [Green Version]
- Makarevich, P.I.; Dergilev, K.V.; Tsokolaeva, Z.I.; Boldyreva, M.A.; Shevchenko, E.K.; Gluhanyuk, E.V.; Gallinger, J.O.; Menshikov, M.Y.; Parfyonova, Y.V. Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS ONE 2018, 13, e0197566. [Google Scholar] [CrossRef]
- Hassinen, I.; Hartikainen, J.; Hedman, A.; Kivelä, A.; Saraste, A.; Knuuti, J.; Husso, M.; Mussalo, H.; Hedman, M.; Toivanen, P. Adenoviral intramyocardial VEGF-D gene transfer increases myocardial perfusion in refractory angina patients. Circulation 2015, 132, A11987. [Google Scholar] [CrossRef]
- Hartikainen, J.; Hassinen, I.; Hedman, A.; Kivelä, A.; Saraste, A.; Knuuti, J.; Husso, M.; Mussalo, H.; Hedman, M.; Rissanen, T.T. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: A phase I/IIa study with 1-year follow-up. Eur. Heart J. 2017, 38, 2547–2555. [Google Scholar] [CrossRef] [Green Version]
- Itoh, N.; Ohta, H.; Nakayama, Y.; Konishi, M. Roles of FGF signals in heart development, health, and disease. Front. Cell Dev. Biol. 2016, 4, 110. [Google Scholar] [CrossRef] [Green Version]
- Khosravi, F.; Ahmadvand, N.; Bellusci, S.; Sauer, H. The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair. Front. Cell Dev. Biol. 2021, 9, 1217. [Google Scholar] [CrossRef]
- Xie, Y.; Su, N.; Yang, J.; Tan, Q.; Huang, S.; Jin, M.; Ni, Z.; Zhang, B.; Zhang, D.; Luo, F.; et al. FGF/FGFR signaling in health and disease. Signal Transduct. Target. Ther. 2020, 5, 181. [Google Scholar] [CrossRef]
- Henry, T.D.; Grines, C.L.; Watkins, M.W.; Dib, N.; Barbeau, G.; Moreadith, R.; Andrasfay, T.; Engler, R.L. Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 2007, 50, 1038–1046. [Google Scholar] [CrossRef] [Green Version]
- Kaski, J.C.; Consuegra-Sanchez, L. Evaluation of ASPIRE trial: A Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin. Biol. Ther. 2013, 13, 1749–1753. [Google Scholar] [CrossRef]
- Wang, L.S.; Wang, H.; Zhang, Q.L.; Yang, Z.J.; Kong, F.X.; Wu, C.T. Hepatocyte Growth Factor Gene Therapy for Ischemic Diseases. Hum. Gene Ther. 2018, 29, 413–423. [Google Scholar] [CrossRef]
- Yuan, B.; Zhao, Z.; Zhang, Y.R.; Wu, C.T.; Jin, W.G.; Zhao, S.; Wangl, W.; Zhang, Y.Y.; Zhu, X.L.; Wang, L.S.; et al. Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In Vivo 2008, 22, 629–632. [Google Scholar]
- Chen, B.; Tao, Z.; Zhao, Y.; Chen, H.; Yong, Y.; Liu, X.; Wang, H.; Wu, Z.; Yang, Z.; Yuan, L. Catheter-based intramyocardial delivery (NavX) of adenovirus achieves safe and accurate gene transfer in pigs. PLoS ONE 2013, 8, e53007. [Google Scholar] [CrossRef] [Green Version]
- Rong, S.L.; Wang, X.L.; Zhang, C.Y.; Song, Z.H.; Cui, L.H.; He, X.F.; Li, X.J.; Du, H.J.; Li, B. Transplantation of HGF gene-engineered skeletal myoblasts improve infarction recovery in a rat myocardial ischemia model. PLoS ONE 2017, 12, e0175807. [Google Scholar] [CrossRef] [Green Version]
- Sun, Z.; Lee, C.J.; Mejia-Guerrero, S.; Zhang, Y.; Higuchi, K.; Li, R.K.; Medin, J.A. Neonatal transfer of membrane-bound stem cell factor improves survival and heart function in aged mice after myocardial ischemia. Hum. Gene Ther. 2012, 23, 1280–1289. [Google Scholar] [CrossRef]
- Ishikawa, K.; Fish, K.; Aguero, J.; Yaniz-Galende, E.; Jeong, D.; Kho, C.; Tilemann, L.; Fish, L.; Liang, L.; Eltoukhy, A.A.; et al. Stem cell factor gene transfer improves cardiac function after myocardial infarction in swine. Circ. Heart Fail. 2015, 8, 167–174. [Google Scholar] [CrossRef] [Green Version]
- Frangogiannis, N.G. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol. Asp. Med. 2019, 65, 70–99. [Google Scholar] [CrossRef]
- Hinderer, S.; Schenke-Layland, K. Cardiac fibrosis—A short review of causes and therapeutic strategies. Adv. Drug Deliv. Rev. 2019, 146, 77–82. [Google Scholar] [CrossRef]
- Bektik, E.; Fu, J.D. Ameliorating the Fibrotic Remodeling of the Heart through Direct Cardiac Reprogramming. Cells 2019, 8, 679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, E.; McCloy, R.; Jordan, A.; Falconer, K.; Dykes, I.M. Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart. J. Cardiovasc. Dev. Dis. 2021, 8, 72. [Google Scholar] [CrossRef] [PubMed]
- Ghiroldi, A.; Piccoli, M.; Ciconte, G.; Pappone, C.; Anastasia, L. Regenerating the human heart: Direct reprogramming strategies and their current limitations. Basic Res. Cardiol. 2017, 112, 68. [Google Scholar] [CrossRef]
- Lee, S.; Park, B.-W.; Lee, Y.J.; Ban, K.; Park, H.-J. In vivo combinatory gene therapy synergistically promotes cardiac function and vascular regeneration following myocardial infarction. J. Tissue Eng. 2020, 11, 2041731420953413. [Google Scholar] [CrossRef]
- Lee, D.H.; Kim, T.M.; Kim, J.K.; Park, C. ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease. Theranostics 2019, 9, 5694–5705. [Google Scholar] [CrossRef]
- Chang, Y.; Lee, E.; Kim, J.; Kwon, Y.W.; Kwon, Y.; Kim, J. Efficient in vivo direct conversion of fibroblasts into cardiomyocytes using a nanoparticle-based gene carrier. Biomaterials 2019, 192, 500–509. [Google Scholar] [CrossRef]
- Isomi, M.; Sadahiro, T.; Fujita, R.; Abe, Y.; Yamada, Y.; Akiyama, T.; Mizukami, H.; Shu, T.; Fukuda, K.; Ieda, M. Direct reprogramming with Sendai virus vectors repaired infarct hearts at the chronic stage. Biochem. Biophys. Res. Commun. 2021, 560, 87–92. [Google Scholar] [CrossRef]
- Adapala, R.K.; Kanugula, A.K.; Paruchuri, S.; Chilian, W.M.; Thodeti, C.K. TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation. Basic Res. Cardiol. 2020, 115, 14. [Google Scholar] [CrossRef]
- Anger, M.; Scheufele, F.; Ramanujam, D.; Meyer, K.; Nakajima, H.; Field, L.J.; Engelhardt, S.; Sarikas, A. Genetic ablation of Cullin-RING E3 ubiquitin ligase 7 restrains pressure overload-induced myocardial fibrosis. PLoS ONE 2020, 15, e0244096. [Google Scholar] [CrossRef]
- Wu, Y.; Zhou, L.; Liu, H.; Duan, R.; Zhou, H.; Zhang, F.; He, X.; Lu, D.; Xiong, K.; Xiong, M.; et al. LRP6 downregulation promotes cardiomyocyte proliferation and heart regeneration. Cell Res. 2021, 31, 450–462. [Google Scholar] [CrossRef]
- Zhou, H.; Yang, J.; Xin, T.; Zhang, T.; Hu, S.; Zhou, S.; Chen, G.; Chen, Y. Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1α/CXC chemokine receptor 4 pathway. Mol. Med. Rep. 2015, 11, 4063–4072. [Google Scholar] [CrossRef] [Green Version]
- Zhu, H.; Jin, Q.; Li, Y.; Ma, Q.; Wang, J.; Li, D.; Zhou, H.; Chen, Y. Melatonin protected cardiac microvascular endothelial cells against oxidative stress injury via suppression of IP3R-[Ca 2+] c/VDAC-[Ca 2+] m axis by activation of MAPK/ERK signaling pathway. Cell Stress Chaperones 2018, 23, 101–113. [Google Scholar] [CrossRef]
- Saparov, A.; Ogay, V.; Nurgozhin, T.; Chen, W.C.; Mansurov, N.; Issabekova, A.; Zhakupova, J. Role of the immune system in cardiac tissue damage and repair following myocardial infarction. Inflamm. Res. 2017, 66, 739–751. [Google Scholar] [CrossRef]
- Wang, X.; Song, Q. Mst1 regulates post-infarction cardiac injury through the JNK-Drp1-mitochondrial fission pathway. Cell. Mol. Biol. Lett. 2018, 23, 21. [Google Scholar] [CrossRef] [Green Version]
- Rodius, S.; de Klein, N.; Jeanty, C.; Sánchez-Iranzo, H.; Crespo, I.; Ibberson, M.; Xenarios, I.; Dittmar, G.; Mercader, N.; Niclou, S.P.; et al. Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity. Sci. Rep. 2020, 10, 2896. [Google Scholar] [CrossRef]
- Liu, X.; Yuan, X.; Liang, G.; Zhang, S.; Zhang, G.; Qin, Y.; Zhu, Q.; Xiao, Q.; Hou, N.; Luo, J.D. BRG1 protects the heart from acute myocardial infarction by reducing oxidative damage through the activation of the NRF2/HO1 signaling pathway. Free Radic. Biol. Med. 2020, 160, 820–836. [Google Scholar] [CrossRef]
- Liu, X.; Zhu, Q.; Zhang, M.; Yin, T.; Xu, R.; Xiao, W.; Wu, J.; Deng, B.; Gao, X.; Gong, W.; et al. Isoliquiritigenin Ameliorates Acute Pancreatitis in Mice via Inhibition of Oxidative Stress and Modulation of the Nrf2/HO-1 Pathway. Oxid. Med. Cell. Longev. 2018, 2018, 7161592. [Google Scholar] [CrossRef]
- Datta Chaudhuri, R.; Banik, A.; Mandal, B.; Sarkar, S. Cardiac-specific overexpression of HIF-1α during acute myocardial infarction ameliorates cardiomyocyte apoptosis via differential regulation of hypoxia-inducible pro-apoptotic and anti-oxidative genes. Biochem. Biophys. Res. Commun. 2021, 537, 100–108. [Google Scholar] [CrossRef]
- Li, F.; Yang, Y.; Xue, C.; Tan, M.; Xu, L.; Gao, J.; Xu, L.; Zong, J.; Qian, W. Zinc Finger Protein ZBTB20 protects against cardiac remodelling post-myocardial infarction via ROS-TNFα/ASK1/JNK pathway regulation. J. Cell. Mol. Med. 2020, 24, 13383–13396. [Google Scholar] [CrossRef]
- Tanwir, K.; Javed, M.T.; Shahid, M.; Akram, M.S.; Ali, Q. Antioxidant defense systems in bioremediation of organic pollutants. In Handbook of Bioremediation; Academic Press: Cambridge, MA, USA, 2021; pp. 505–521. [Google Scholar]
- Ma, L.L.; Kong, F.J.; Ma, Y.J.; Guo, J.J.; Wang, S.J.; Dong, Z.; Sun, A.J.; Zou, Y.Z.; Ge, J.B. Hypertrophic preconditioning attenuates post-myocardial infarction injury through deacetylation of isocitrate dehydrogenase 2. Acta Pharmacol. Sin. 2021, in press. [Google Scholar] [CrossRef]
- Lee, J.H.; Go, Y.; Kim, D.Y.; Lee, S.H.; Kim, O.H.; Jeon, Y.H.; Kwon, T.K.; Bae, J.H.; Song, D.K.; Rhyu, I.J.; et al. Isocitrate dehydrogenase 2 protects mice from high-fat diet-induced metabolic stress by limiting oxidative damage to the mitochondria from brown adipose tissue. Exp. Mol. Med. 2020, 52, 238–252. [Google Scholar] [CrossRef]
- Çakmak, H.A.; Demir, M. MicroRNA and Cardiovascular Diseases. Balkan Med. J. 2020, 37, 60–71. [Google Scholar] [CrossRef]
- Shi, C.C.; Pan, L.Y.; Zhao, Y.Q.; Li, Q.; Li, J.G. MicroRNA-323-3p inhibits oxidative stress and apoptosis after myocardial infarction by targeting TGF-β2/JNK pathway. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 6961–6970. [Google Scholar] [CrossRef]
- Zhu, F.; Yu, Z.; Li, D. miR-187 Modulates Cardiomyocyte Apoptosis and Oxidative Stress in Myocardial Infarction Mice via Negatively Regulating DYRK2; Research Square: Durham, NC, USA, 2021. [Google Scholar]
- Li, D.; Zhou, J.; Yang, B.; Yu, Y. microRNA-340-5p inhibits hypoxia/reoxygenation-induced apoptosis and oxidative stress in cardiomyocytes by regulating the Act1/NF-κB pathway. J. Cell. Biochem. 2019, 120, 14618–14627. [Google Scholar] [CrossRef]
- Trembinski, D.J.; Bink, D.I.; Theodorou, K.; Sommer, J.; Fischer, A.; van Bergen, A.; Kuo, C.C.; Costa, I.G.; Schürmann, C.; Leisegang, M.S.; et al. Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. Nat. Commun. 2020, 11, 2039. [Google Scholar] [CrossRef] [PubMed]
- Ellery, J.; Dickson, L.; Cheung, T.; Ciuclan, L.; Bunyard, P.; Mack, S.; Buffham, W.J.; Farnaby, W.; Mitchell, P.; Brown, D.; et al. Identification of compounds acting as negative allosteric modulators of the LPA1 receptor. Eur. J. Pharmacol. 2018, 833, 8–15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Han, F.; Chen, Q.; Su, J.; Zheng, A.; Chen, K.; Sun, S.; Wu, H.; Jiang, L.; Xu, X.; Yang, M.; et al. MicroRNA-124 regulates cardiomyocyte apoptosis and myocardial infarction through targeting Dhcr24. J. Mol. Cell. Cardiol. 2019, 132, 178–188. [Google Scholar] [CrossRef] [PubMed]
- Dong, Y.; Chen, H.; Gao, J.; Liu, Y.; Li, J.; Wang, J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J. Mol. Cell. Cardiol. 2019, 136, 27–41. [Google Scholar] [CrossRef] [Green Version]
- Teringova, E.; Tousek, P. Apoptosis in ischemic heart disease. J. Transl. Med. 2017, 15, 87. [Google Scholar] [CrossRef] [Green Version]
- Yuan, T.; Krishnan, J. Non-coding RNAs in Cardiac Regeneration. Front. Physiol. 2021, 12, 358. [Google Scholar] [CrossRef]
- Yan, M.J.; Tian, Z.S.; Zhao, Z.H.; Yang, P. MiR-31a-5p protects myocardial cells against apoptosis by targeting Tp53. Mol. Med. Rep. 2018, 17, 3898–3904. [Google Scholar] [CrossRef]
- Wang, Y.; Cui, X.; Wang, Y.; Fu, Y.; Guo, X.; Long, J.; Wei, C.; Zhao, M. Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin. J. Cell Physiol. 2018, 233, 6344–6351. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Zhong, J.; Zeng, Z.; Wang, H.; Li, J.; Liu, X.; Yang, X. MiR-181c protects cardiomyocyte injury by preventing cell apoptosis through PI3K/Akt signaling pathway. Cardiovasc. Diagn. Ther. 2020, 10, 849–858. [Google Scholar] [CrossRef]
- Wang, Q.S.; Zhou, J.; Li, X. LncRNA UCA1 protects cardiomyocytes against hypoxia/reoxygenation induced apoptosis through inhibiting miR-143/MDM2/p53 axis. Genomics 2020, 112, 574–580. [Google Scholar] [CrossRef]
- Hao, S.; Liu, X.; Sui, X.; Pei, Y.; Liang, Z.; Zhou, N. Long non-coding RNA GAS5 reduces cardiomyocyte apoptosis induced by MI through sema3a. Int. J. Biol. Macromol. 2018, 120, 371–377. [Google Scholar] [CrossRef]
- Long, B.; Li, N.; Xu, X.X.; Li, X.X.; Xu, X.J.; Guo, D.; Zhang, D.; Wu, Z.H.; Zhang, S.Y. Long noncoding RNA FTX regulates cardiomyocyte apoptosis by targeting miR-29b-1-5p and Bcl2l2. Biochem. Biophys. Res. Commun. 2018, 495, 312–318. [Google Scholar] [CrossRef]
- Zeng, Y.; Du, W.W.; Wu, Y.; Yang, Z.; Awan, F.M.; Li, X.; Yang, W.; Zhang, C.; Yang, Q.; Yee, A.; et al. A Circular RNA Binds to and Activates AKT Phosphorylation and Nuclear Localization Reducing Apoptosis and Enhancing Cardiac Repair. Theranostics 2017, 7, 3842–3855. [Google Scholar] [CrossRef]
- Zhu, Y.; Zhao, P.; Sun, L.; Lu, Y.; Zhu, W.; Zhang, J.; Xiang, C.; Mao, Y.; Chen, Q.; Zhang, F. Overexpression of circRNA SNRK targets miR-103-3p to reduce apoptosis and promote cardiac repair through GSK3β/β-catenin pathway in rats with myocardial infarction. Cell Death Discov. 2021, 7, 84. [Google Scholar] [CrossRef]
- Garikipati, V.N.S.; Verma, S.K.; Cheng, Z.; Liang, D.; Truongcao, M.M.; Cimini, M.; Yue, Y.; Huang, G.; Wang, C.; Benedict, C.; et al. Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS/VEGF-A axis. Nat. Commun. 2019, 10, 4317. [Google Scholar] [CrossRef]
- Imbalzano, E.; Mandraffino, G.; Casciaro, M.; Quartuccio, S.; Saitta, A.; Gangemi, S. Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: A systematic review. Heart Fail. Rev. 2016, 21, 463–473. [Google Scholar] [CrossRef]
- Fan, L.; Liu, B.; Guo, R.; Luo, J.; Li, H.; Li, Z.; Xu, W. Elevated plasma S100A1 level is a risk factor for ST-segment elevation myocardial infarction and associated with post-infarction cardiac function. Int. J. Med. Sci. 2019, 16, 1171–1179. [Google Scholar] [CrossRef] [Green Version]
- Jungi, S.; Fu, X.; Segiser, A.; Busch, M.; Most, P.; Fiedler, M.; Carrel, T.; Tevaearai Stahel, H.; Longnus, S.L.; Most, H. Enhanced Cardiac S100A1 Expression Improves Recovery from Global Ischemia-Reperfusion Injury. J. Cardiovasc. Transl. Res. 2018, 11, 236–245. [Google Scholar] [CrossRef]
- Sleczka, B.G.; Levesque, P.C.; Adam, L.P.; Olah, T.V.; Shipkova, P. LC/MS/MS-based quantitation of pig and human S100A1 protein in cardiac tissues: Application to gene therapy. Anal. Biochem. 2020, 602, 113766. [Google Scholar] [CrossRef]
- Donato, R.; Sorci, G.; Giambanco, I. S100A6 protein: Functional roles. Cell. Mol. Life Sci. 2017, 74, 2749–2760. [Google Scholar] [CrossRef]
- Mofid, A.; Newman, N.S.; Lee, P.J.; Abbasi, C.; Matkar, P.N.; Rudenko, D.; Kuliszewski, M.A.; Chen, H.H.; Afrasiabi, K.; Tsoporis, J.N.; et al. Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia-Reperfusion. J. Am. Heart Assoc. 2017, 6, e004738. [Google Scholar] [CrossRef] [Green Version]
- Cho, H.M.; Lee, K.H.; Shen, Y.M.; Shin, T.J.; Ryu, P.D.; Choi, M.C.; Kang, K.S.; Cho, J.Y. Transplantation of hMSCs Genome Edited with LEF1 Improves Cardio-Protective Effects in Myocardial Infarction. Mol. Ther. Nucleic Acids 2020, 19, 1186–1197. [Google Scholar] [CrossRef]
- Meng, D.; Han, S.; Jeong, I.S.; Kim, S.W. Interleukin 10-Secreting MSCs via TALEN-Mediated Gene Editing Attenuates Left Ventricular Remodeling after Myocardial Infarction. Cell. Physiol. Biochem. 2019, 52, 728–741. [Google Scholar] [CrossRef]
- Meng, X.; Zheng, M.; Yu, M.; Bai, W.; Zuo, L.; Bu, X.; Liu, Y.; Xia, L.; Hu, J.; Liu, L.; et al. Transplantation of CRISPRa system engineered IL10-overexpressing bone marrow-derived mesenchymal stem cells for the treatment of myocardial infarction in diabetic mice. J. Biol. Eng. 2019, 13, 49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaminsky, S.M.; Quach, L.; Chen, S.; Pierre-Destine, L.; Van de Graaf, B.; Monette, S.; Rosenberg, J.B.; De, B.P.; Sondhi, D.; Hackett, N.R.; et al. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum. Gene Ther. Clin. Dev. 2013, 24, 38–46. [Google Scholar] [CrossRef]
- Anttila, V.; Saraste, A.; Knuuti, J.; Jaakkola, P.; Hedman, M.; Svedlund, S.; Lagerström-Fermér, M.; Kjaer, M.; Jeppsson, A.; Gan, L.M. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial. Mol. Ther. Methods Clin. Dev. 2020, 18, 464–472. [Google Scholar] [CrossRef]
- Weng, Y.; Li, C.; Yang, T.; Hu, B.; Zhang, M.; Guo, S.; Xiao, H.; Liang, X.J.; Huang, Y. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 2020, 40, 107534. [Google Scholar] [CrossRef] [PubMed]
- Meng, Z.; O’Keeffe-Ahern, J.; Lyu, J.; Pierucci, L.; Zhou, D.; Wang, W. A new developing class of gene delivery: Messenger RNA-based therapeutics. Biomater. Sci. 2017, 5, 2381–2392. [Google Scholar] [CrossRef] [PubMed]
- Teijaro, J.R.; Farber, D.L. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021, 21, 195–197. [Google Scholar] [CrossRef] [PubMed]
- Turner, J.S.; O’Halloran, J.A.; Kalaidina, E.; Kim, W.; Schmitz, A.J.; Zhou, J.Q.; Lei, T.; Thapa, M.; Chen, R.E.; Case, J.B.; et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021, 596, 109–113. [Google Scholar] [CrossRef] [PubMed]
- Magadum, A.; Kaur, K.; Zangi, L. mRNA-Based Protein Replacement Therapy for the Heart. Mol. Ther. 2019, 27, 785–793. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.S.; Hwang, H.Y.; Cho, K.R.; Park, E.A.; Lee, W.; Paeng, J.C.; Lee, D.S.; Kim, H.K.; Sohn, D.W.; Kim, K.B. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: Phase I clinical study. Gene Ther. 2013, 20, 717–722. [Google Scholar] [CrossRef] [Green Version]
- Ishikawa, K.; Fish, K.M.; Tilemann, L.; Rapti, K.; Aguero, J.; Santos-Gallego, C.G.; Lee, A.; Karakikes, I.; Xie, C.; Akar, F.G.; et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol. Ther. 2014, 22, 2038–2045. [Google Scholar] [CrossRef] [Green Version]
- Watanabe, S.; Ishikawa, K.; Fish, K.; Oh, J.G.; Motloch, L.J.; Kohlbrenner, E.; Lee, P.; Xie, C.; Lee, A.; Liang, L.; et al. Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure. J. Am. Coll. Cardiol. 2017, 70, 1744–1756. [Google Scholar] [CrossRef]
- Hammond, H.K.; Penny, W.F.; Traverse, J.H.; Henry, T.D.; Watkins, M.W.; Yancy, C.W.; Sweis, R.N.; Adler, E.D.; Patel, A.N.; Murray, D.R.; et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients with Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016, 1, 163–171. [Google Scholar] [CrossRef] [Green Version]
# | Study Title | Disease | Treatment Mechanism (Intervention) | Estimated Enrollment | Current Status and Phase | Trial Number |
---|---|---|---|---|---|---|
1 | Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) | Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases, Heart Diseases | Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human VEGF | 44 participants | Recruiting, Phase I/II | NCT04125732 |
2 | Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris (ReGenHeart) | Refractory Angina Pectoris, Coronary Artery Disease | A catheter mediated endocardial adenovirus-mediated VEGF-D (AdVEGF-D) regenerative gene transfer in patients with refractory angina to whom revascularization cannot be performed | 180 participants | Recruiting, Phase II | NCT03039751 |
3 | AZD8601 Study in CABG Patients (EPICCURE) | Heart Failure | Epicardial injections of VEGF-A165 mRNA formulated in biocompatible citrate-buffered saline (AZD8601) in a 10-min extension of cardioplegia during the CABG surgery under PET imaging | 11 participants | Active, not recruiting, Phase II | NCT03370887 |
4 | Ad5FGF-4 In Patients with Refractory Angina Due to Myocardial Ischemia (AFFIRM) | Angina, Stable | A single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human FGF-4 (Ad5FGF-4) | 160 participants | Not yet recruiting, Phase III | NCT02928094 |
5 | Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction | Ischemic Heart Disease, Acute Myocardial Infarction | VM202RY injected via transendocardial route using C-Cathez® catheter in subjects with acute MI | 108 participants | Recruiting, Phase II | NCT03404024 |
6 | Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID-3) | Congestive Heart Failure, Systolic Heart Failure | A single intracoronary infusion of adeno-associated virus serotype 1 vector expressing the transgene for sarco(endo)plasmic reticulum Ca2+ ATPase 2a isoform (SRD-001) | 56 participants | Not yet recruiting, Phase I/II | NCT04703842 |
7 | NAN-101 in Patients with Class III Heart Failure (NAN-CS101) | Heart Failure, Heart Disease, Ischemic Cardiovascular Diseases, Heart Arrhythmia | A single intracoronary infusion of chimeric adeno-associated virus serotype 2/8 with an active I-1 transgene | 12 participants | Recruiting, Phase I | NCT04179643 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, Y.; Zharkinbekov, Z.; Sarsenova, M.; Yeltay, G.; Saparov, A. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration. Int. J. Mol. Sci. 2021, 22, 9206. https://doi.org/10.3390/ijms22179206
Kim Y, Zharkinbekov Z, Sarsenova M, Yeltay G, Saparov A. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration. International Journal of Molecular Sciences. 2021; 22(17):9206. https://doi.org/10.3390/ijms22179206
Chicago/Turabian StyleKim, Yevgeniy, Zharylkasyn Zharkinbekov, Madina Sarsenova, Gaziza Yeltay, and Arman Saparov. 2021. "Recent Advances in Gene Therapy for Cardiac Tissue Regeneration" International Journal of Molecular Sciences 22, no. 17: 9206. https://doi.org/10.3390/ijms22179206